Closed-loop insulin delivery in type 1 diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 1, 2012, Pages 105-117

  Thabit, Hood ^a,b   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Algorithm; Closed loop; Continuous glucose sensor; Insulin pump

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; SHORT ACTING INSULIN;

ACCURACY; ALGORITHM; ARTIFICIAL PANCREAS; BIOSENSOR; BLOOD GLUCOSE MONITORING; CARBOHYDRATE INTAKE; CLINICAL EFFECTIVENESS; CLOSED LOOP INSULIN DELIVERY; DIABETIC PATIENT; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MONITOR; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 84860606886     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.12.003     Document Type: Review

References (73)

1. Cryer P.E. The barrier of hypoglycemia in diabetes. Diabetes 2008, 57(12):3169-3176.
2. Unger J., Parkin C. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. Postgrad Med 2011, 123(4):81-91.
3. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011, 7(7):385-395.
4. Klonoff D.C. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005, 28(5):1231-1239.
5. Pickup J., Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002, 25(3):593-598.
6. Bequette B.W. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol Ther 2005, 7(1):28-47.
7. Weller C., Linder M., Macaulay A., et al. Continuous in vivo determination of blood glucose in human subjects. Ann N Y Acad Sci 1960, 87:658-668.
8. Kadish A. Automation control of blood sugar. I. A servomechanism for glucose monitoring and control. Am J Med Electron 1964, 3:82-86.
9. Albisser A.M., Leibel B.S., Ewart T.G., et al. An artificial endocrine pancreas. Diabetes 1974, 23(5):389-396.
10. Pfeiffer E.F., Thum C., Clemens A.H. The artificial beta cell-a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system). Horm Metab Res 1974, 6(5):339-342.
11. Renard E., Costalat G., Chevassus H., et al. Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients. Diabetes Res Clin Pract 2006, 74(Suppl 2):S173-S177.
12. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med 2006, 23(1):1-12.
13. Renard E., Place J., Cantwell M., et al. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 2010, 33(1):121-127.
14. Steil G.M., Rebrin K. Closed-loop insulin delivery-what lies between where we are and where we are going?. Expert Opin Drug Deliv 2005, 2(2):353-362.
15. Renard E., Costalat G., Chevassus H., et al. Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab 2006, 32(5 Pt 2):497-502.
16. Mastrototaro J. The MiniMed Continuous Glucose Monitoring System (CGMS). J Pediatr Endocrinol Metab 1999, 12(Suppl 3):751-758.
17. Oliver N.S., Toumazou C., Cass A.E., et al. Glucose sensors: a review of current and emerging technology. Diabet Med 2009, 26(3):197-210.
18. Feldman B., Brazg R., Schwartz S., et al. A continuous glucose sensor based on wired enzyme technology-results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther 2003, 5(5):769-779.
19. Tamada J.A., Garg S., Jovanovic L., et al. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA 1999, 282(19):1839-1844.
20. Bolinder J., Ungerstedt U., Arner P. Microdialysis measurement of the absolute glucose concentration in subcutaneous adipose tissue allowing glucose monitoring in diabetic patients. Diabetologia 1992, 35(12):1177-1180.
21. Valgimigli F., Lucarelli F., Scuffi C., et al. Evaluating the clinical accuracy of GlucoMen®Day: a novel microdialysis-based continuous glucose monitor. J Diabetes Sci Technol 2010, 4(5):1182-1192.
22. Pickup J.C., Freeman S.C., Sutton A.J. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011, 343:d3805.
23. Peters A. Do we really need continuous glucose monitoring?. Diabetes Technol Ther 2009, 11(Suppl 1):S128-S130.
24. McQueen R., Ellis S., Campbell J., et al. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc 2011, 9:13.
25. Selam S. CSII in Europe: where are we, where are we going? An analysis of articles published in Infusystems International. Diabetes Res Clin Pract 2006, 74(Suppl 2):S23-126.
26. Bergenstal R.M., Tamborlane W.V., Ahmann A., et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010, 363(4):311-320.
27. Zisser H., Jovanovic L. OmniPod Insulin Management System: patient perceptions, preference, and glycemic control. Diabetes Care 2006, 29(9):2175.
28. Bode B.W. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine. Endocr Pract 2011, 17(2):271-280.
29. Zisser H., Wagner R., Pleus S., et al. Clinical performance of three bolus calculators in subjects with type 1 diabetes mellitus: a head-to-head-to-head comparison. Diabetes Technol Ther 2010, 12(12):955-961.
30. Clemens A.H. Feedback control dynamics for glucose controlled insulin infusion system. Med Prog Technol 1979, 6(3):91-98.
31. Marchetti G., Barolo M., Jovanovic L., et al. An improved PID switching control strategy for type 1 diabetes. IEEE Trans Biomed Eng 2008, 55(3):857-865.
32. Steil G.M., Rebrin K., Darwin C., et al. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006, 55(12):3344-3350.
33. Castle J.R., Engle J.M., El Youssef J., et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010, 33(6):1282-1287.
34. Weinzimer S.A., Steil G.M., Swan K.L., et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008, 31(5):934-939.
35. Magni L., Raimondo D.M., Bossi L., et al. Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 2007, 1(6):804-812.
36. Hovorka R., Canonico V., Chassin L.J., et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004, 25(4):905-920.
37. El-Khatib F.H., Russell S.J., Nathan D.M., et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010, 2(27):27ra27.
38. Hovorka R., Allen J.M., Elleri D., et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010, 375(9716):743-751.
39. Steil G.M., Panteleon A.E., Rebrin K. Closed-loop insulin delivery-the path to physiological glucose control. Adv Drug Deliv Rev 2004, 56(2):125-144.
40. Shimoda S., Nishida K., Sakakida M., et al. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Front Med Biol Eng 1997, 8(3):197-211.
41. Camacho E.F., Bordons C. Model predictive control 1999, Springer-Verlag, London.
42. Atlas E., Nimri R., Miller S., et al. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 2010, 33(5):1072-1076.
43. Kovatchev B., Patek S., Dassau E., et al. Control to range for diabetes: functionality and modular architecture. J Diabetes Sci Technol 2009, 3(5):1058-1065.
44. Ellingsen C., Dassau E., Zisser H., et al. Safety constraints in an artificial pancreatic beta cell: an implementation of model predictive control with insulin on board. J Diabetes Sci Technol 2009, 3(3):536-544.
45. Elleri D., Allen J.M., Nodale M., et al. Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with Type 1 diabetes. Diabet Med 2010, 27(4):480-484.
46. Dassau E., Zisser H., Palerm C C., et al. Modular artificial beta-cell system: a prototype for clinical research. J Diabetes Sci Technol 2008, 2(5):863-872.
47. Steil G.M., Palerm C.C., Kurtz N., et al. The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011, 96(5):1402-1408.
48. Hovorka R., Kumareswaran K., Harris J., et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011, 342:d1855.
49. Kowalski A.J. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther 2009, 11(Suppl 1):S113-S119.
50. Buckingham B., Wilson D.M., Lecher T., et al. Duration of nocturnal hypoglycemia before seizures. Diabetes Care 2008, 31(11):2110-2112.
51. Choudhary P., Shin J., Wang Y., et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011, 34(9):2023-2025.
52. Danne T., Kordonouri O., Holder M., et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011, 13(11):1129-1134.
53. Buckingham B., Chase H.P., Dassau E., et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care 2010, 33(5):1013-1017.
54. Cengiz E., Swan K.L., Tamborlane W.V., et al. Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technol Ther 2009, 11(4):207-210.
55. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991, 90(4):450-459.
56. Davis E.A., Keating B., Byrne G.C., et al. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997, 20(1):22-25.
57. Elleri D., Acerini C.L., Allen J.M., et al. Parental attitudes towards overnight closed-loop glucose control in children with type 1 diabetes. Diabetes Technol Ther 2010, 12(1):35-39.
58. Wilinska M.E., Budiman E.S., Taub M.B., et al. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol 2009, 3(5):1109-1120.
59. Elleri D., Allen J.M., Kumareswaran K., et al. Day-and-night closed loop (CL) glucose control in adolescents with type 1 diabetes (T1D). Diabetes 2011, 60(Suppl 1):A41.
60. Murphy H.R., Elleri D., Allen J.M., et al. Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 2011, 34(2):406-411.
61. Murphy H.R., Kumareswaran K., Elleri D., et al. Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: a randomized crossover case series. Diabetes Care 2011, 34(12):2527-2529.
62. McGarraugh G., Bergenstal R. Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring System. Diabetes Technol Ther 2009, 11(3):145-150.
63. Garg S.K., Voelmle M., Gottlieb P.A. Time lag characterization of two continuous glucose monitoring systems. Diabetes Res Clin Pract 2010, 87(3):348-353.
64. Weinstein R.L., Schwartz S.L., Brazg R.L., et al. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 2007, 30(5):1125-1130.
65. Keenan D.B., Mastrototaro J.J., Voskanyan G., et al. Delays in minimally invasive continuous glucose monitoring devices: a review of current technology. J Diabetes Sci Technol 2009, 3(5):1207-1214.
66. Wei C., Lunn D.J., Acerini C.L., et al. Measurement delay associated with the Guardian RT continuous glucose monitoring system. Diabet Med 2010, 27(1):117-122.
67. Tsalikian E., Kollman C., Tamborlane W.B., et al. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care 2006, 29(10):2200-2204.
68. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002, 4(5):673-682.
69. Carroll M.F., Schade D.S. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract 2005, 11(1):55-64.
70. Riazi A., Pickup J., Bradley C. Daily stress and glycaemic control in Type 1 diabetes: individual differences in magnitude, direction, and timing of stress-reactivity. Diabetes Res Clin Pract 2004, 66(3):237-244.
71. Turner B.C., Jenkins E., Kerr D., et al. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care 2001, 24(11):1888-1893.
72. Buckingham B., Cobry E., Clinton P., et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009, 11(2):93-97.
73. Kovatchev B., Cobelli C., Renard E., et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol 2010, 4(6):1374-1381.